Title:
METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2016/181225
Kind Code:
A3
Abstract:
A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER 1 /Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.
Inventors:
D'HONDT ERIK (BE)
MOLINA VILA MIGUEL ANGEL (ES)
MOLINA VILA MIGUEL ANGEL (ES)
Application Number:
PCT/IB2016/000888
Publication Date:
January 12, 2017
Filing Date:
May 12, 2016
Export Citation:
Assignee:
BIOVEN 3 LTD (GB)
International Classes:
A61K39/00; A61K31/517; A61K31/5377; A61K31/7084; A61K39/395; A61K45/06
Foreign References:
| US20120294867A1 | 2012-11-22 |
Other References:
JIAN Y. CHENG ET AL: "CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma", HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 8, no. 12, 1 December 2012 (2012-12-01), US, pages 1799 - 1801, XP055306187, ISSN: 2164-5515, DOI: 10.4161/hv.21744
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; August 2009 (2009-08-01), LIU D ET AL: "Inhibitory effect of gefitinib combined with DNA vaccine targeting EGFR against mouse lung cancer Lewis cells", XP002762436, Database accession no. EMB-2009506152
D V PARUMS: "Status of immune therapy in Non-Small Cell Lung Cancer (NSCLC)", DRUGS OF THE FUTURE, 1 July 2014 (2014-07-01), pages 469 - 477, XP055306224, Retrieved from the Internet [retrieved on 20160928], DOI: 10.1358/dof.2014.39.7.2185935
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; August 2009 (2009-08-01), LIU D ET AL: "Inhibitory effect of gefitinib combined with DNA vaccine targeting EGFR against mouse lung cancer Lewis cells", XP002762436, Database accession no. EMB-2009506152
D V PARUMS: "Status of immune therapy in Non-Small Cell Lung Cancer (NSCLC)", DRUGS OF THE FUTURE, 1 July 2014 (2014-07-01), pages 469 - 477, XP055306224, Retrieved from the Internet
Download PDF: